Form 4: IN8BIO Director Emily Fairbairn Acquires 724K Shares

IN8BIO Director Emily Fairbairn reported an acquisition of 724,637 common shares at $1.38 per share, increasing her indirect beneficial ownership.

Summary

• Director Emily Fairbairn acquired 724,637 shares of IN8BIO, INC. common stock on December 22, 2025.
• The transaction was executed at a price of $1.38 per share.
• The acquired shares are indirectly held by the Malcom and Emily Fairbairn 2010 CRUT, where Ms. Fairbairn serves as a trustee.
• Beneficial ownership also includes 3,044 shares held by Valley High Limited Partnership and 923 shares held by Emily T. Fairbairn Roth IRA.
• All reported share numbers have been adjusted to reflect a 1-for-30 reverse stock split of the Issuer's common stock, effective June 3, 2025.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares by a director indicates confidence in the company's prospects. This insider buying is generally viewed as a positive signal by the market.

Positives

• A director, Emily Fairbairn, acquired a significant number of shares (724,637 shares), which can be interpreted as a vote of confidence in the company's future prospects.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• The acquired securities are held by the Malcom and Emily Fairbairn 2010 CRUT, where the Reporting Person (Emily Fairbairn) is a trustee.
• 3,044 shares are held by Valley High Limited Partnership, where Emily Fairbairn's spouse is the sole managing partner and has voting and investment power.
• 923 shares are held by Emily T. Fairbairn Roth IRA, over which Emily Fairbairn exercises control and has voting and investment power.

Stakeholder Impact

• Shareholders: The director's acquisition of a substantial number of shares could be perceived as a positive signal, potentially boosting investor confidence in the company's future.

Key Dates

Recommendation

The director's acquisition of a substantial number of shares signals confidence, which is a positive indicator. However, a Form 4 filing primarily discloses an insider transaction and does not provide a comprehensive view of the company's financial health or strategic direction. Investors should consider this insider buying in conjunction with the company's broader financial reports and market conditions before making a definitive investment decision. Therefore, a 'hold' recommendation is prudent, suggesting investors maintain their current position while awaiting more detailed financial reports.

Keywords

IN8BIO, INAB, Emily Fairbairn, Director, Insider Trading, Stock Acquisition, Form 4, SEC Filing, Common Stock, Reverse Stock Split